Radiodermatitis - Pipeline Review, H1 2018

  • ID: 4542983
  • Report
  • 33 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • SK Chemicals Co Ltd
  • MORE
Radiodermatitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H1 2018, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

Report Highlights:

This latest pipeline guide Radiodermatitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • SK Chemicals Co Ltd
  • MORE
Introduction

Report Coverage

Radiodermatitis - Overview

Radiodermatitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiodermatitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiodermatitis - Companies Involved in Therapeutics Development

Daiichi Sankyo Co Ltd

SK Chemicals Co Ltd

Radiodermatitis - Drug Profiles

cerium oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Pulmonary Inflammation, Radiodermatitis and Xerostomia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RS-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKI-2162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tempol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZM-241385 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Radiodermatitis - Dormant Projects

Radiodermatitis - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Radiodermatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Radiodermatitis - Pipeline by SK Chemicals Co Ltd, H1 2018

Radiodermatitis - Dormant Projects, H1 2018

Radiodermatitis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Radiodermatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Daiichi Sankyo Co Ltd
  • SK Chemicals Co Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll